Search Results
54 protocol(s) meet the specified criteria
100305Open  
Phase I, Open-Label, Multicenter, Dose-Escalation Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human Ox40l, for Intratumoral Injection to Patients with Advanced Malignancies

100308Open  
Phase I/IB, Open-Label, Multicenter, Dose-Escalation Study of NIS793 in Combination with PDR001 in Adult Patients with Advanced Malignancies

100703Not Open *
Phase IA/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent on in combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors

100890Open  
Phase IB (Open-Label) / Phase II (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine with or without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

102309Open  
Phase IB, Open-Label, Dose-Finding Study to Evaluate the Safety and Tolerability of Cabometyx and Avelumab in Patients with Metastatic Renal Cell Carcinoma (mRCC)

102829Open  
Phase IB Dose-Escalation Study of Cabozantinib Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

102932Open  
Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

103123Open  
Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

103657Open  
Exploratory Phase IB Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Breast Cancer

103695Not Open *
Pilot Trial Evaluating the Combination of Reolysin and Carfilzomib in Multiple Myeloma

103706Open  
Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies

103837Open  
Phase IB/II Study to Assess the Safety, Tolerability, and Efficacy of BGB-290 in Combination with Radiation Therapy and/or Temozolomide in Subjects with First-Line or Recurrent/Refractory Glioblastoma

103945Open  
Phase I Open-Label Trial of a Combination of Nivolumab and Bevacizumab in Patients with Advanced and/or Metastatic Hepatocellular Carcinoma

104258Open  
Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

104564Not Open *
Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) after Prior Platinum Containing First-Line Chemotherapy

104630Open  
Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid Tumors (FIM)

105164Open  
Phase IB/II Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors

105925Open  
Phase I First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma and Subjects with Relapsed or Refractory Acute Myeloid Leukemia

107029Open  
Two-Part Phase I/II Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

107831Open  
Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab

108884Open  
Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients with Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-Line Setting (APPEASE)

110520Open  
Open-Label, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors and Lymphomas

110522Open  
Phase I and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

110969Open  
Phase I Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

111266Open  
Open-Label, Multicenter Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma (GBM)

112012Open  
Open Label, Phase I Study of SC-004 as Monotherapy and in Combination with ABBV-181 in Subjects with Epithelial Ovarian, including Fallopian Tube and Primary Peritoneal and Endometrial Cancers

112055Open  
Phase IB Study of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

112664Open  
Phase I Dose-Escalation Study of the Selective PKC-beta Inhibitor MS-553 in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

112811Open  
Phase IB/II Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Binimetinib with or without Talazoparib in Patients with Locally Advanced or Metastatic RAS-Mutant Solid Tumors

113380Open  
Phase I/II Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations

113384Open  
Phase IB, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with Cisplatin plus Gemcitabine and PEGPH20 in Combination with Atezolizumab and Cisplatin plus Gemcitabine Compared with Cisplatin plus Gemcitabine in Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

44704Open  
Assessment of Primary and Metastatic Brain Tumor Hypoxia with 18F-Fluoromisonidazole, [18F]fluoro-2-deoxy-D-glucose (FDG) and [15O]water (H215O)

61077Open  
Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells with Myeloablative Conditioning for High-Risk Hematologic Malignancies

71940Open  
Stereotactic Radiosurgery Dose Escalation for Brain Metastases

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

80792Open  
Randomized, Double-Blind, Phase IB/II Study of PF-04449913 in Combination with Azacitidine in Patients with Previously Untreated Intermediate-2 or High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-Lineage Dysplasia, or Chronic Myelomonocytic Leukemia

81405Not Open *
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

84004Open  
Molecular Analysis for Therapy Choice (MATCH)

87144Open  
Phase IB Trial of a Combination of mFOLFIRI with MEK162 in Patients with Advanced KRAS Positive Metastatic Colorectal Cancers

87238Open  
Phase I/II Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin Lymphoma

87788Open  
Open-Label, Phase IB Study of ACP-196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma

87799Open  
Phase I Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type

88893Open  
Phase IB Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

89466Open  
Phase IB, Open-Label, Multicenter, Dose-Escalation Trial of Intratumoral Injections of SD-101 in Combination with Pembrolizumab in Patients with Metastatic Melanoma

89510Open  
STARTRK-2 (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases-2): An Open-Label, Multicenter, Global, Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

90576Not Open *
Phase I, Open-Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas

93426Open  
Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

94141Open  
Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

97417Not Open *
Phase I/IIA First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

97422Open  
Phase I/IB Study of Subcutaneous Recombinant Human hetIL-15 Alone and in Combination with PDR001 in Adults with Metastatic Cancers

99128Open  
Open-Label Phase I/IIA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer

99707Open  
Phase I, Non-Randomized, Open-Label/Phase II Randomized, Blinded Study of ProTmune versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies

99903Open  
Proof-of-Concept, Pilot Study of Pembrolizumab in Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype

99906Open  
Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors